Introducing TotalAssist
Launching July 1, 2026, TotalAssist is a major step forward in how patient assistance works: simple, flexible, and centered on real-world patient needs.
TotalAssist is the nation’s largest and most comprehensive charitable patient assistance portfolio
Starting July 1, 2026, Patient Advocate Foundation will launch TotalAssist—a unified financial assistance program designed to make it easier for patients to start and stay on treatment. By bringing together the strengths of Patient Advocate Foundation and PAN Foundation, TotalAssist is a major step forward in how patient assistance works: simple, flexible, and centered on real-world patient needs.
What is TotalAssist?
TotalAssist is the nation’s largest and most comprehensive charitable patient assistance portfolio. At launch, it will include over 130 disease-specific and health equity financial assistance funds, supporting patients across a wide range of conditions—from cancer and rare diseases to chronic and complex illnesses.
TotalAssist helps patients pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, office visit charges the day of treatment, and administration charges related to treatment. TotalAssist does not limit how grants can be used. Instead, TotalAssist allows patients to apply their grant toward multiple healthcare expenses, helping reduce gaps in care.
Through our TotalAssist program, patients may use grants for:
- Medication copays, coinsurance, and deductibles
- Health insurance premiums
- Office visit charges the day of treatment
- Administration charges related to treatment
This comprehensive approach reflects how patients actually experience care—and helps remove the financial barriers that too often interrupt treatment.
How it supports patients
At a time when healthcare costs continue to rise and more people are struggling to afford care, TotalAssist expands access, reduces complexity, and strengthens the safety net for patients nationwide.
Broad and reliable coverage
- Over 130 disease-specific funds covering high-need conditions nationwide
- Use of grants to cover more eligible out-of-pocket healthcare costs: medication copays, coinsurance, and deductibles, health insurance premiums, office visit charges the day of treatment, and administration charges related to treatment
- Financial assistance for treatments that are FDA-approved, listed in official compendia, and published in evidence-based guidelines
- Guaranteed grant amounts, with additional support provided automatically when available
Easier, faster access
- No waitlists and first-come, first-served enrollment
- Real-time fund notifications by email or text when funds open
- Instant eligibility decisions at the time of application
Simplifying the patient journey
- Simple online portals for patients, healthcare professionals, pharmacies, and nonprofits
- Diagnosis verification handled directly with providers—reducing burden on patients
- Streamlined medical claims, insurance premiums, and patient reimbursements: All processed in-house and can be easily uploaded via the portal
- Point of sale pharmacy claims processing: Pharmacy claims are processed at the point of sale through a virtual pharmacy card, making it easy for both patients and pharmacies
Putting patients at the center
TotalAssist is designed to address patient realities and not add administrative complexity.
Key patient-focused features include:
- Six-month lookback coverage, allowing eligible patients to apply assistance to qualifying expenses incurred before enrollment
- Dedicated patient support specialists to guide patients and caregivers through enrollment
- Concierge support to onboard and support providers and pharmacies
Patients also benefit from trusted tools like FundFinder, which helps identify alternative assistance when funds are unavailable, and the National Financial Resource Directory, which connects people to additional support beyond healthcare costs.
Sign up for announcements about our programs and initiatives, and reminders about the launch of TotalAssist. You’ll be the first to know when changes and new opportunities are on the horizon.
Advancing health equity
Patient Advocate Foundation pioneered health equity funds to ensure assistance reaches the people and communities who need it most. TotalAssist will include over 20 health equity funds, serving patients in hundreds of counties across dozens of states identified through a data-driven methodology using the CDC’s Social Vulnerability Index and disease incidence data.
Eligibility for health equity funds is determined by zip code, with all other requirements consistent with standard disease funds, helping reduce disparities while maintaining fairness and transparency.
TotalAssist Funds
Below is the list of funds that will be included at the TotalAssist launch on July 1, 2026.
As needs continue to evolve, the funds offered through TotalAssist will continue to grow, expanding support where gaps exist and ensuring assistance remains responsive to patients nationwide. When TotalAssist launches on July 1, 2026, fund eligibility may change with patient access in mind. We will continue to update this page and our help center as information is released.
TotalAssist Funds (starting July 1, 2026)
A-L
Acromegaly
Acute myeloid leukemia (AML)
Alzheimer’s disease health equity
Amyloidosis
Asthma
Asthma health equity
Atopic dermatitis
Basal cell carcinoma (BCC)
Biliary tract cancer
Bipolar disorder
Bladder cancer
Breast cancer
Breast cancer health equity
Cancer genetic and genomic testing
Cervical cancer
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Chronic kidney disease (CKD)
Chronic lymphocytic leukemia (CLL)
Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease health equity
Chronic spontaneous urticaria (CSU)
Colorectal cancer
Coronary artery disease (CAD) health equity
COVID-19 & post-COVID
Cushing’s disease or syndrome
Cystic fibrosis (CF)
Diabetic retinopathy
Diffuse large B-cell lymphoma (DLBCL)
Duchenne muscular dystrophy (DMD)
Eosinophilic esophagitis
Fabry disease
Fabry disease health equity
Follicular lymphoma
Gastrointestinal stromal tumors (GIST)
Gaucher disease
Gaucher disease health equity
Glioblastoma multiforme (GBM)
Graft vs. host disease (GvHD)
Heart failure
Heart failure health equity
Hemolytic uremic syndrome (HUS)
Hemophilia
Hemophilia health equity
Hepatitis B
Hepatitis B health equity
Hepatitis C
Hepatitis C health equity
HIV, AIDS, and prevention
HIV, AIDS, and prevention health equity
Hypercholesterolemia
Hyperkalemia
Hypophosphatasia
Immune thrombocytopenic purpura (ITP)
Inflammatory bowel disease (IBD)
Inherited retinal disease (IRD)
Lipodystrophy
Liver cancer
Long-chain fatty acid oxidation disorders (LC-FOAD)
Lysosomal acid lipase deficiency (LAL-D)
Lupus
Lupus health equity
M-Z
Macular degeneration and related diseases
Mantle cell lymphoma (MCL)
Melanoma
Metabolic dysfunction-associated steatohepatitis (MASH)
Metastatic breast cancer
Metastatic colorectal cancer
Metastatic colorectal cancer health equity
Metastatic gastric cancer
Metastatic melanoma
Metastatic prostate cancer
Mucopolysaccharidosis (MPS) type III
Mucopolysaccharidosis (MPS) type VII
Mucopolysaccharidosis (MPS) type VII health equity
Multiple myeloma
Multiple myeloma health equity
Multiple sclerosis (MS)
Multiple sclerosis health equity
Myasthenia gravis
Myelodysplastic syndromes (MDS)
Narcolepsy
Neurofibromatosis (NF)
Neuromyelitis optica spectrum disorder (NMOSD)
Neurotrophic keratitis (NK)
Neutropenia
Non-Hodgkin’s lymphoma
Non-small cell lung cancers (NSCLC)
Non-small cell lung cancers health equity
Obesity
Osteoporosis
Ovarian cancer
Ovarian cancer health equity
Pancreatic cancer
Parkinson’s disease
Parkinson’s disease health equity
Paroxysmal nocturnal hemoglobinuria (PNH)
Pemphigus vulgaris (PV)
Periodic paralysis
Peripheral vascular and artery disease
Philadelphia chromosome negative myeloproliferative neoplasms (MPN)
Pompe disease
Pompe disease health equity
Prostate cancer
Prostate cancer health equity
Psoriasis
Psoriatic arthritis (PsA)
Pulmonary fibrosis
Pulmonary hypertension
Renal cell carcinoma (RCC)
Retinal vein occlusion (RVO)
Rett syndrome (RS)
Rheumatoid arthritis (RA)
Schizophrenia
Short bowel syndrome (SBS)
Sickle cell disease
Skin cancer
Small cell lung cancer (SCLC)
Social needs assessment and intervention
Soft tissue sarcoma
Spinal muscular atrophy (SMA)
Spinal muscular atrophy (SMA) health equity
Stroke
Thyroid eye disease
Transportation
Type 2 diabetes
Type 2 diabetes health equity
Ulcerative colitis (UC)
Uterine cancer
Uterine cancer health equity
Uveitis
Virology testing health equity
Von Willebrand disease
Waldenstrom macroglobulinemia (WM)
Help center
Use our help center to find answers to questions that impact you, so you can make the most informed decisions.
News
Read the latest news about our merger and programs, access our media kit, and sign up for updates.
Contact us
Reach out with any questions or concerns. We will get in touch with you as quickly as possible.